Advertisement

Smoking Behavior and Cessation (Nicotine Addiction): Are Genetic Factors Involved in Smoking Behavior?

  • Tetsuya Kubota
  • Akihito Yokoyama
Chapter
Part of the Respiratory Disease Series: Diagnostic Tools and Disease Managements book series (RDSDTDM)

Abstract

Tobacco smoking is a major risk factor for a number of health problems, including cancer, chronic obstructive pulmonary disease, lung fibrosis, and cardiovascular disease. Tobacco smoke contains thousands of harmful, carcinogenics and toxic substances. Particularly, nicotine is the causative substance in tobacco smoke that leads to dependence. Smoking behavior is addictive, and this addiction is categorized among the behavioral and neurodevelopmental disorders in the tenth revision of the International Classification of Diseases. Once absorbed, nicotine directly affects the nervous system. However, the sensitivity for developing nicotine addiction varies between individuals. Affinity to nicotinic receptors and related enzymatic activity can influence the metabolism of nicotine. Although environmental factors are associated with nicotine addiction, meta-analyses of genome-wide association studies have revealed that genetic factors contribute to the risks of developing such clinical conditions. Regarding genetic factors, single nucleotide polymorphisms of nicotinic acetylcholine receptors and cytochrome P450 (CYP) family 2 subfamily A polypeptides are associated with nicotine dependence. Smoking cessation would help prevent the numerous health problems associated with smoking. An effective smoking cessation strategy would be to combine both behavioral and pharmacological therapies, including nicotine replacement therapy and a partial nicotinic receptor agonist.

Keywords

Smoking behavior Smoking cessation Nicotine addiction Genetic factor 

References

  1. 1.
    Goodman J. Timeline. In: Tobacco in history and culture. An encyclopedia. Farmington Hills, MI: Thomson Gale; 2005. p. xiii–xvi.Google Scholar
  2. 2.
    WHO. Tobacco fact sheet. Geneva: World Health Organization Media Centre; 2016. http://www.who.int/mediacentre/factsheets/fs339/en/. Accessed 1 Jan 2017.Google Scholar
  3. 3.
    International Agency for Research on Cancer IARC. Monographs on the evaluation of carcinogenic risks to humans. Personal habits and indoor combustions, vol. 100E. Lyon: WHO press; 2012.Google Scholar
  4. 4.
    Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, Ghissassi FE, Bouvard V, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103:1827–39.  https://doi.org/10.1093/jnci/djr483.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79–115.  https://doi.org/10.1124/pr.57.1.3.CrossRefPubMedGoogle Scholar
  6. 6.
    Armitage A, Dollery C, Houseman T, Kohner E, Lewis PJ, Turner D. Absorption of nicotine from small cigars. Clin Pharmacol Ther. 1978;23:143–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Fattinger K, Verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther. 1997;281:1238–46.PubMedGoogle Scholar
  8. 8.
    Yoshida T, Sakane N, Umekawa T, Kondo M. Effect of nicotine on sympathetic nervous system activity of mice subjected to immobilization stress. Physiol Behav. 1994;55:53–7.  https://doi.org/10.1016/0031-9384(94)90009-4.CrossRefPubMedGoogle Scholar
  9. 9.
    Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis. 2002;23:1979–2004.  https://doi.org/10.1093/carcin/23.12.1979.CrossRefPubMedGoogle Scholar
  10. 10.
    Church DF, Prior WA. Free-radical chemistry of cigarette smoke and its toxicologyical implications. Environ Health Perspect. 1985;64:111–26.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol. 2006;533:222–39.CrossRefPubMedGoogle Scholar
  12. 12.
    Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J. 2005;149:565–72.  https://doi.org/10.1016/j.ahj.2004.09.040.CrossRefPubMedGoogle Scholar
  13. 13.
    Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses---United States, 2000--2004. Morb Mortal Wkly Rep. 2008;57:1226–8.Google Scholar
  14. 14.
    Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138:16–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–8.  https://doi.org/10.1136/bmj.1.6077.1645.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, et al. A genome –wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5:e1000421.  https://doi.org/10.1371/journal.pgen.1000421.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mohamed Hoesein FAA, Wauters E, Janssens W, Groen HJM, Smolonska J, Wijmenga C, Postma DS, et al. Variants in the 15q24/25 locus associate with lung function decline in active smokers. PLoS One. 2013;8:e53219.  https://doi.org/10.1371/journal.pone.0053219.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Budulac SE, Vonk JM, Postma DS, Siedlinski M, Timens W, Boezen MH. Nicotinic acetylcholine receptor variants are related to smoking habits, but not directly to COPD. PLoS One. 2012;7:e33386.  https://doi.org/10.1371/journal.pone.0033386.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer. 2012;131:2724–32.  https://doi.org/10.1002/ijc.27816.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Alexandrov LB, Ju YS, Haase K, Loo PV, Martincorena I, Nik-Zainal S, Totoki Y, et al. Mutational signatures associated with tobacco smoking in human cancers. Science. 2016;354:618–22.  https://doi.org/10.1126/science.aag0299.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang S, Takayama K, Tanaka K, Takeshita M, Nakagaki N, Ijichi K, Li H, et al. Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. J Thorac Oncol. 2013;8:719–25.  https://doi.org/10.1097/JTO.0b013e31828b51d4.CrossRefPubMedGoogle Scholar
  22. 22.
    Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047–53.  https://doi.org/10.1016/S0140-6736(07)60464-4.CrossRefPubMedGoogle Scholar
  23. 23.
    Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295–303.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pogun S, Yararbas G, Nesil T, Kanit L. Sex differences in nicotine preference. J Neurosci Res. 2017;95:148–62.  https://doi.org/10.1002/jnr.23858.CrossRefPubMedGoogle Scholar
  25. 25.
    Pérez-Stable EJ, Herrera B, Jacob P III, Benowitz NL. Nicotine metabolism and intake in black and white smokers. JAMA. 1998;280:152–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Li MD, Ma JZ, Cheng R, Dupont RT, Williams NJ, Crews KM, Payne TJ, et al. A genome-wide scan to identify loci for smoking rate in the Framingham Heart Study population. BMC Genet. 2003;4(Suppl 1):S103.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Pérez-Rubio G, Sansores R, Ramírez-Venegas A, Camarena Á, Pérez-Rodríguez ME, Falfán-Valencia R. Nicotin addiction development: from epidemiology to genetic factors. Rev Invest Clin. 2015;67:333–43.PubMedGoogle Scholar
  28. 28.
    Unwin N. Refined Structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol. 2005;346:967–89.  https://doi.org/10.1016/j.jmb.2004.12.031.CrossRefPubMedGoogle Scholar
  29. 29.
    Labarca C, Schwarz J, Deshpande P, Schwarz S, Nowak MW, Fonck C, Nashmi R, et al. Point mutant mice with hypersensitive α4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci. 2001;98:2786–91.  https://doi.org/10.1073/pnas.041582598.CrossRefPubMedGoogle Scholar
  30. 30.
    Loukola A, Hällfors J, Korhonen T, Kaprio J. Genetics and smoking. Curr Addict Rep. 2014;1:75–82.  https://doi.org/10.1007/s40429-013-0006-3.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Li MD. The genetics of nicotine dependence. Curr Psychiatry Rep. 2006;8:158–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Loukola A, Buckwald J, Gupta R, Palviainen T, Hällfors J, Tikkanen E, Korhonen T, et al. A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet. 2015;11:e1005498.  https://doi.org/10.1371/journal.pgen.1005498.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Gellert C, Scöttker B, Brenner H. Smoking and all-cause mortality in old people. Arch Intern Med. 2012;172:837–44.CrossRefPubMedGoogle Scholar
  34. 34.
    Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2013;11:CD000146.  https://doi.org/10.1002/14651858.CD000146.pub4.CrossRefGoogle Scholar
  35. 35.
    Cahill K, Stevens S, Perera R, Lancaser T. Pharmacological intervenetions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329.  https://doi.org/10.1002/14651858.CD009329.pub2.
  36. 36.
    Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6:300.  https://doi.org/10.1186/1471-2458-6-300.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Hematology and Respiratory MedicineKochi UniversityNankokuJapan

Personalised recommendations